Sustainable antimicrobial resistance surveillance: time for a global funding mechanism
Issued Date
2025-01-01
Resource Type
ISSN
14733099
eISSN
14744457
Scopus ID
2-s2.0-85214346926
Pubmed ID
39706207
Journal Title
The Lancet Infectious Diseases
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet Infectious Diseases (2025)
Suggested Citation
Painter C., Limmathurotsakul D., Roberts T., van Doorn H.R., Mayxay M., Lubell Y., Day N.P.J., Turner P., Ashley E.A. Sustainable antimicrobial resistance surveillance: time for a global funding mechanism. The Lancet Infectious Diseases (2025). doi:10.1016/S1473-3099(24)00649-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102740
Title
Sustainable antimicrobial resistance surveillance: time for a global funding mechanism
Author's Affiliation
Faculty of Tropical Medicine, Mahidol University
Mahidol Oxford Tropical Medicine Research Unit
Amsterdam Institute for Global Health and Development
Oxford University Clinical Research Unit
Ministry of Health Laos
National University of Singapore
Mahosot Hospital, Lao
Nuffield Department of Medicine
Cambodia Oxford Medical Research Unit
Mahidol Oxford Tropical Medicine Research Unit
Amsterdam Institute for Global Health and Development
Oxford University Clinical Research Unit
Ministry of Health Laos
National University of Singapore
Mahosot Hospital, Lao
Nuffield Department of Medicine
Cambodia Oxford Medical Research Unit
Corresponding Author(s)
Other Contributor(s)
Abstract
Antimicrobial resistance (AMR) is predicted to outstrip malaria, HIV, and tuberculosis combined as the leading infectious cause of death by 2050. Strengthening the knowledge and evidence base for AMR with surveillance and research is one of the five main objectives of the WHO Global Action Plan on AMR. While recent efforts to strengthen diagnosis and surveillance have been encouraging, these are unlikely to be sustainable without continued funding support in most low-resource settings. We estimated the continued costs of a standard national AMR surveillance system in low-income and middle-income countries (LMICs). For 46 LMICs, the costs would account for more than 2% of their total domestic general government health expenditure (GGHE-D), and for 28 of these countries, the costs are more than 5% of their total GGHE-D. This high cost is not sustainable without a long-term global financing mechanism.
